Skip to content
StackItSmart
AHuman RCT or meta-analysis
CardiovascularCardiotoxicNeuropsychiatric

Albuterol

Salbutamol

Albuterol (salbutamol) is a short-acting, selective beta-2 adrenergic agonist approved as an inhaled bronchodilator for asthma and, in some countries, given orally. In performance and physique circles it is used off-label as a stimulant "cutting"/lipolytic and mild anabolic agent, often as a legal-status stand-in for clenbuterol. The main risks are cardiovascular and metabolic: it drives tachycardia and palpitations, causes fine tremor, lowers serum potassium, and can provoke arrhythmias, especially in the setting of hypokalemia, hypoxia, dehydration, or pre-existing heart disease. Human data show that only supra-therapeutic oral dosing (not standard inhaler use) produces measurable body-composition or performance effects, and observational data link oral/nebulized beta-2 agonists to increased cardiovascular death and ischemic heart disease. This is educational information only, not medical advice, and does not endorse non-prescription use; anyone using it should be under medical supervision with regular bloodwork.

Clinical readoutPED-adjacent · beta2-agonist
Hepatic strainLow
CardiovascularHigh
HPTA suppressionNone
Half-life
3.8 h
Route
Inhaled
Evidence
A
Active
Bronchodilator effect o…
3.8 h7.6 h11.4 h15.2 h19 h
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Terminal plasma half-life about 3.8 hours after oral or intravenous dosing in healthy adults (PMID 3653233); inhaled short-acting formulations act rapidly but are cleared over a similar range.
Pharmacology

Mechanism of action

Albuterol is a selective beta-2 adrenoceptor agonist. In airway smooth muscle it activates Gs-coupled beta-2 receptors, raising intracellular cyclic AMP, relaxing bronchial smooth muscle and producing bronchodilation. The same beta-2/cAMP signaling in skeletal muscle promotes a shift toward faster (type IIa) myosin heavy-chain fibers and hypertrophy of those fibers, and in adipose/hepatic tissue increases lipolysis, glycogenolysis and metabolic rate; these systemic beta-2 effects underlie both its off-label "anabolic/lipolytic" reputation and its adverse effects (tachycardia, tremor, hypokalemia from beta-2-mediated intracellular potassium shift).
Kinetics

Pharmacokinetics

Half-life

Terminal plasma half-life about 3.8 hours after oral or intravenous dosing in healthy adults (PMID 3653233); inhaled short-acting formulations act rapidly but are cleared over a similar range.

Active duration

Bronchodilator effect of a standard inhaled/immediate-release dose lasts roughly 4-6 hours; peak plasma concentrations occur 1-3 hours after oral dosing (PMID 3653233).

Route

Inhaled (metered-dose inhaler/nebulizer), oral (tablet/syrup), and intravenous; absolute oral bioavailability is about 44% due to first-pass metabolism (PMID 3653233).

Metabolism & clearance

Undergoes extensive first-pass hepatic/gut metabolism, primarily sulfate conjugation to the inactive metabolite salbutamol 4'-O-sulfate, with renal excretion of parent drug and metabolite; mean clearance about 439 mL/min/1.73 m2 (PMID 3653233). PK is documented here for washout and clinician discussion, not for evading drug testing.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Bronchodilation and improved airway function (increased FEV1) after inhalation (PMID 25894531).
  • With supra-therapeutic oral dosing (16 mg/day) during resistance training, augmented hypertrophy of type IIa muscle fibers and greater sprint mean power output, but maximal strength gains were no greater than placebo (PMID 33357007).
  • Oral albuterol added to the later stages of a resistance-training program produced somewhat greater knee-extensor/flexor strength gains than placebo (PMID 15705021).
  • Favorable short-term shifts in serum lipids with oral dosing (lower total and LDL cholesterol, higher HDL) without marked impairment of glucose tolerance (PMID 8637445).
  • Acute metabolic effects at rest after inhaled supra-therapeutic dosing: increased plasma free fatty acids, glycerol and lactate, and decreased plasma potassium (PMID 15459835).
  • Standard/therapeutic inhaled doses (400-1600 mcg) do not improve endurance, strength, or power in non-asthmatic athletes (PMID 24451697; PMID 25894531); a single supra-therapeutic 800 mcg inhaled dose produced only a small ~1.9% endurance cycling change (PMID 15459835).
Safety

Adverse effects by system

Cardiovascular

Dose-related tachycardia and palpitations are predictable class effects; higher blood salbutamol concentrations were found in patients who died of asthma (about 2.5x controls), and it is thought toxic concentrations can provoke tachyarrhythmias under hypoxia and hypokalemia. Nebulized and oral beta-2 agonists are associated in observational data with increased cardiovascular death, ischemic heart disease, and cardiac failure (PMID 14719995).

Hepatic

Not a recognized hepatotoxin. Albuterol undergoes extensive first-pass hepatic/gut sulfation to an inactive metabolite (PMID 3653233; PMID 30296863), but no meaningful signal of drug-induced liver injury is described in the human literature retrieved.

Endocrine / HPTA

Albuterol is a beta-2 adrenergic agonist, not a hormonal/androgenic agent, and does not act on the hypothalamic-pituitary-gonadal axis. Metabolic-endocrine effects are sympathomimetic: transient rises in glucose, insulin, free fatty acids, glycerol and lactate, but oral dosing did not markedly impair glucose tolerance in healthy men (PMID 8637445; PMID 15459835).

Reproductive

Beta-2 agonism relaxes uterine smooth muscle, a pharmacologic effect rather than a toxicity; no data on impairment of fertility in the performance-use context were identified in the retrieved literature.

Neuropsychiatric

Fine tremor and headache are common, predictable, dose-related effects (PMID 14719995); nervousness, restlessness and insomnia are recognized sympathomimetic effects of beta-2 agonists though not well quantified in the primary sources retrieved here.

Renal

No direct nephrotoxicity is documented in the retrieved human literature. The main renally-relevant effect is beta-2-mediated hypokalemia (intracellular potassium shift), an electrolyte disturbance rather than kidney injury (PMID 15459835; PMID 14719995).

Hematologic

No clinically significant hematologic effects are documented in the retrieved human literature.

Dermatologic

No significant dermatologic toxicity is documented in the retrieved human literature; hypersensitivity reactions are described in product labeling but were not characterized in the primary studies retrieved.

Recovery

HPTA suppression & recovery

Suppression: None expected / not applicable

Albuterol is a beta-2 adrenergic agonist, not an androgen, anabolic steroid, or SERM, and there is no evidence that it suppresses the hypothalamic-pituitary-gonadal axis; post-cycle SERM therapy is not relevant to this compound. Any concern about hormonal status should be evaluated with bloodwork and directed by an endocrinologist. If it is used alongside hormonal agents, recovery of those separate axes is variable and individual, and any single-SERM approach for that unrelated context should still be directed by an endocrinologist.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Serum potassium and full electrolyte panel (beta-2 agonists lower potassium)Fasting glucose (and HbA1c if diabetic or at risk)Fasting lipid panelBaseline and follow-up resting heart rate and blood pressureECG if palpitations, chest symptoms, or pre-existing cardiac disease

Cadence: Establish a baseline before any use; recheck electrolytes, heart rate and blood pressure early during use (within days to weeks) and if dose is increased or symptoms develop; ongoing periodic bloodwork under a clinician's direction.

Warning signs — seek care
  • Palpitations, racing or irregular heartbeat, chest pain
  • Severe or persistent tremor, marked anxiety or agitation
  • Muscle weakness, cramps, or palpitations suggesting low potassium
  • Lightheadedness, fainting, or shortness of breath
  • Paradoxical worsening of breathing after inhaled use
Do not use if

Contraindications

  • Known hypersensitivity to albuterol/salbutamol.
  • Pre-existing tachyarrhythmias or significant cardiovascular disease (ischemic heart disease, heart failure, arrhythmia) given association with increased cardiovascular death and arrhythmia risk (PMID 14719995).
  • Uncorrected hypokalemia or conditions/co-medications that lower potassium (diuretics, other stimulants), because beta-2 agonists further reduce serum potassium and raise arrhythmia risk (PMID 15459835; PMID 14719995).
  • Hyperthyroidism, uncontrolled hypertension, and situations of hypoxia, which amplify cardiac and arrhythmic risk (PMID 14719995).
  • Diabetes/glucose dysregulation warrants caution given sympathomimetic metabolic effects (PMID 8637445).
Combinations

Interaction profile

  • MajorWith an anabolic steroid: Additive cardiovascular strain
  • MajorWith a stimulant: Additive cardiovascular strain
  • ModerateWith a SARM: Additive cardiovascular strain
  • MajorWith thyroid hormone: Additive cardiovascular strain
  • ModerateWith a GLP-1 / incretin agonist: Additive cardiovascular strain
  • ModerateWith a melanocortin agonist: Additive hypertension
  • MajorWith insulin: Metabolic / glucose
  • MajorWith a QT-prolonging drug: QT prolongation
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Educational information only, not medical advice, and not an endorsement of non-prescription use; use should occur under a clinician with regular bloodwork. 21+ only.
  • Standard inhaler doses used for asthma do not produce the body-composition or performance effects people seek; the human effects seen came from supra-therapeutic oral dosing that also carries the greatest cardiovascular and electrolyte risk (PMID 33357007; PMID 24451697).
  • Have baseline heart rate, blood pressure, potassium and an ECG (if any cardiac history) before use, and monitor them during use (PMID 14719995; PMID 15459835).
  • Do not combine with other stimulants, potassium-lowering drugs (e.g., diuretics), or use while dehydrated/hypoxic, as these compound arrhythmia risk (PMID 15459835; PMID 14719995).
  • Stop and seek medical care for palpitations, irregular heartbeat, chest pain, fainting, severe tremor/anxiety, muscle weakness or cramps (possible low potassium), or worsened breathing after inhaled use.
  • This compound is not a hormonal agent and does not require SERM/PCT; any hormonal concerns should be directed to an endocrinologist.
Evidence

Citations (9)

Every clinical claim above is tied to a primary source. Overall evidence grade A — graded to the best available evidence for its core claims.

  1. 01

    Oral salbutamol 16 mg/day during 11 weeks of resistance training augmented type IIa fiber hypertrophy and sprint mean power output, but maximal muscle strength increased no more than placebo; salbutamol is characterized as a muscle-anabolic drug.

    RCTPMID 33357007 ↗

  2. 02

    Oral albuterol (titrated to 16 mg/day) added to the later stages of a resistance-training program produced greater knee extensor/flexor strength gains than placebo.

    RCTPMID 15705021 ↗

  3. 03

    Oral albuterol (8 mg twice daily for 14 days) in healthy men lowered total and LDL cholesterol and raised HDL without marked impairment of glucose tolerance.

    CohortPMID 8637445 ↗

  4. 04

    A single supra-therapeutic inhaled dose (800 mcg) improved endurance cycling by ~1.9% and, at rest, raised plasma free fatty acids, glycerol and lactate and decreased plasma potassium.

    RCTPMID 15459835 ↗

  5. 05

    Inhaled salbutamol 1600 mcg/day for 6 weeks did not significantly improve endurance, strength, or power in male athletes.

    RCTPMID 24451697 ↗

  6. 06

    Inhaled 400 mcg salbutamol significantly improved FEV1 (lung function) but did not improve 10-km cycling time-trial performance.

    RCTPMID 25894531 ↗

  7. 07

    Beta-2 agonists cause predictable dose-related palpitations, tremor and headache; higher blood salbutamol concentrations were found in asthma deaths (~2.5x controls) with tachyarrhythmia risk under hypoxia/hypokalemia; oral and nebulized beta-2 agonists are associated with increased cardiovascular death, ischemic heart disease and cardiac failure.

    ReviewPMID 14719995 ↗

  8. 08

    Oral salbutamol terminal half-life is about 3.8 hours, absolute oral bioavailability about 44%, peak plasma concentration at 1-3 hours, mean clearance about 439 mL/min/1.73 m2.

    CohortPMID 3653233 ↗

  9. 09

    Salbutamol has poor oral bioavailability due to first-pass hepatic metabolism and a short half-life, with systemic toxicity at high doses.

    PreclinicalPMID 30296863 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice